Search results
Results from the WOW.Com Content Network
Tamsulosin is primarily used for benign prostatic hyperplasia (BPH) and to help with the passage of kidney stones. [13] [14] Tamsulosin, however, appears to be effective only for stones over 4 mm and less than 10 mm in size. [8] Tamsulosin is also used as an add-on treatment for acute urinary retention. People may void more successfully after ...
heart failure. The cardio-selective beta-1 blockers could cause adverse effects including bradycardia, reduced exercise ability, hypotension, atrioventricular nodal blockage and heart failure. [5] Other possible adverse effects include nausea and vomiting, abdominal discomfort, dizziness, weakness, headache, fatigue, and dryness in mouth and ...
The fundamental goal of treatment should be the prevention of the important endpoints of hypertension, such as heart attack, stroke and heart failure. Patient age, associated clinical conditions and end-organ damage also play a part in determining dosage and type of medication administered. [ 3 ]
Alpha-1 blockers are first line treatment for the symptoms of BPH in men. [1] [2] [7] [8] Doxazosin, terazosin, alfuzosin, and tamsulosin have all been well established in treatment to reduce lower urine tract symptoms (LUTS) caused by benign prostatic hyperplasia. They are all believed to be similarly effective for this purpose.
Another treatment for hypertension is using drugs that have both α 1 blocking activity, as well as nonselective β activity, such as Labetalol or carvedilol. [19] In low doses, labetalol and carvedilol can decrease the peripheral resistance and block the effects of isoprenaline to reduce hypertensive symptoms.
This blood clot may then restrict blood flow within the heart, leading to heart tissue damage, or a myocardial infarction, also known as a heart attack. [ 1 ] Coronary thrombosis is most commonly caused as a downstream effect of atherosclerosis , a buildup of cholesterol and fats in the artery walls.
Grade 1 hypertension. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial, also known as ALLHAT, was a randomized, double-blind, active-controlled study comparing at the same time, four different classes of antihypertensive drugs with the rate of coronary heart disease (CHD) events in ‘high-risk’ people with hypertension. [1]
The FDA approved the CardiAssist ECP system for the treatment of angina, acute myocardial infarction and cardiogenic shock under a 510(k) submission in 1980 [1] [failed verification] Since then, additional ECP devices have been cleared by the FDA for use in treating stable or unstable angina pectoris, acute myocardial infarction, cardiogenic shock, and congestive heart failure.